Carboxypeptidase M in apoptosis, adipogenesis and cancer.
Clin Chim Acta
; 415: 306-16, 2013 Jan 16.
Article
em En
| MEDLINE
| ID: mdl-23178445
ABSTRACT
This review covers carboxypeptidase M (CPM) research that appeared in the literature since 2009. The focus is on aspects that are new or interesting from a clinical perspective. Available research tools are discussed as well as their pitfalls and limitations. Evidence is provided to suggest the potential involvement of CPM in apoptosis, adipogenesis and cancer. This evidence derives from the expression pattern of CPM and its putative substrates in cells and tissues. In recent years CPM emerged as a potential cancer biomarker, in well differentiated liposarcoma where the CPM gene is co-amplified with the oncogene MDM2; and in lung adenocarcinoma where coexpression with EGFR correlates with poor prognosis. The available data call for extended investigation of the function of CPM in tumor cells, tumor-associated macrophages, stromal cells and tumor neovascularisation. Such experiments could be instrumental to validate CPM as a therapeutic target.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Tecidos Moles
/
Metaloendopeptidases
/
Adenocarcinoma
/
Biomarcadores Tumorais
/
Lipossarcoma
/
Neoplasias Pulmonares
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article